After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone.
The incidence of a composite of adverse events and a range of adverse outcomes (bleeding, limb ischemia, renal replacement therapy, sepsis) was significantly higher with the use of the microaxial flow pump.
These results of Impella CP are in contrast with those of of IABP in the IABP-SHOCK II trial and venoarterial ECMO in the ECLS-SHOCK trial. Is this because of the device, or because of better patient selection than in prior trials? #ACC24nejm.org/doi/full/10.10…
1/11
#PAC 101 (The Catheter)
A cath lab pt just arrived in your ICU with a pulmonary artery catheter (#PAC) in place.
Your bedside nurse (limited #PAC experience) asks you to walk her through the basic PAC lumens and ports 😱
Fortunately for you, you had bookmarked the 🧵 👇🏻
Our perspective on the vulnerable plaque and vulnerable patient just published in Nature Reviews Cardiology. Please DM me a request with your email address and I would be pleased to send you a journal-approved copy.